专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5725850A Use of CSF-1 to treat tumor burden 失效
标题翻译：使用CSF-1治疗肿瘤负担
公开(公告)号：US5725850A
公开(公告)日：1998-03-10
申请号：US371924
申请日：1995-01-11
申请人： Peter Ralph , Kong T. Chong , James Devlin , Robert Zimmerman , Sharon Lea Aukerman , David B. Ring , Sylvia Hsieh Ma
发明人： Peter Ralph , Kong T. Chong , James Devlin , Robert Zimmerman , Sharon Lea Aukerman , David B. Ring , Sylvia Hsieh Ma
IPC分类号： A61K38/00 , A61K38/19 , A61K38/20 , A61K38/21 , C07K14/53 , C12N15/73
CPC分类号： C12N15/73 , A61K38/18 , A61K38/20 , C07K14/53 , A61K38/00 , Y10S514/885 , Y10S514/887
摘要： A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
摘要翻译：集落刺激因子CSF-1是可用于治疗或预防细菌，病毒或真菌感染，肿瘤，白细胞减少症，伤口和克服化疗诱导的免疫抑制或由其他原因引起的淋巴因子。通过重组方法获得可用量的CSF-1，包括克隆和表达编码该蛋白质的鼠和人DNA序列。

2. 发明授权

US5169774A Monoclonal anti-human breast cancer antibodies 失效
标题翻译：单克隆抗人乳腺癌抗体
公开(公告)号：US5169774A
公开(公告)日：1992-12-08
申请号：US190778
申请日：1988-05-06
申请人： Arthur E. Frankel , David B. Ring , Walter Laird
发明人： Arthur E. Frankel , David B. Ring , Walter Laird
IPC分类号： A61K38/00 , C07K16/30
CPC分类号： C07K16/3015 , A61K38/00 , C07K2317/24 , C07K2317/622 , Y10S436/813 , Y10S530/808 , Y10S530/809 , Y10S530/864
摘要： Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
摘要翻译：与人乳腺癌细胞结合选择性的鼠单克隆抗体或其片段是IgG或IgM，当与蓖麻毒蛋白A链结合时，其对MCF-7，CAMA-1，SKBR- 3或BT-20细胞小于约10nM。描述了用由其制备的抗体或免疫毒素来诊断，监测和治疗人乳腺癌的方法。

3. 发明授权

US4956453A Anti-human ovarian cancer immunotoxins and methods of use thereof 失效
标题翻译：抗人卵巢癌免疫毒素及其使用方法
公开(公告)号：US4956453A
公开(公告)日：1990-09-11
申请号：US69720
申请日：1987-07-06
申请人： Michael J. Bjorn , Arthur E. Frankel , Walter J. Laird , David B. Ring , Jeffrey L. Winkelhake
发明人： Michael J. Bjorn , Arthur E. Frankel , Walter J. Laird , David B. Ring , Jeffrey L. Winkelhake
IPC分类号： A61K38/00 , A61K47/48 , C07K16/30
CPC分类号： C07K16/30 , A61K47/48638 , A61K38/00 , Y10S424/804 , Y10S424/807 , Y10S514/885 , Y10S530/808 , Y10S530/861 , Y10S530/864 , Y10S530/866
摘要： Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals and extending the survial of mammals carrying human ovarian cancer tumors are claimed.
摘要翻译：要求具有下列能力之一的包含细胞毒素部分和选自Fab，Fab'和F（ab'）2结合部分的单克隆抗体结合人卵巢癌组织的抗原结合部分的免疫毒素：对人卵巢癌细胞约10nM或更少的细胞毒性ID50，哺乳动物中人卵巢癌肿瘤生长的延迟或携带人卵巢癌肿瘤的哺乳动物的存活的延长。识别单克隆抗体结合的抗原或表位，并表征免疫毒素。在优选的实施方案中，描述并要求保护包含至少结合人转铁蛋白受体但不阻断转铁蛋白与受体结合的单克隆抗体的抗原结合部分的免疫毒素。还要求保护包含抗转铁蛋白单克隆抗体的F（ab'）2区的免疫毒素。要求杀死人类卵巢癌细胞的方法，延缓哺乳动物中人卵巢癌肿瘤的生长并延长携带人卵巢癌肿瘤的哺乳动物的存活。

4. 发明授权

US07138497B2 Biosynthetic binding proteins for immuno-targeting 失效
公开(公告)号：US07138497B2
公开(公告)日：2006-11-21
申请号：US09887853
申请日：2001-06-21
申请人： Lou L. Houston , David B. Ring
发明人： Lou L. Houston , David B. Ring
IPC分类号： C07K16/28 , C07K16/30 , C07K16/32
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/22 , C07K16/30 , C07K16/3015 , C07K16/3069 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C07K2319/55
摘要： Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

5. 发明授权

US5837846A Biosynthetic binding proteins for immuno-targeting 失效
公开(公告)号：US5837846A
公开(公告)日：1998-11-17
申请号：US461386
申请日：1995-06-05
申请人： James S. Huston , L. L. Houston , David B. Ring , Hermann Oppermann
发明人： James S. Huston , L. L. Houston , David B. Ring , Hermann Oppermann
IPC分类号： C12N15/09 , A61K39/395 , A61K49/00 , A61K51/00 , A61K51/08 , A61P35/00 , C07H21/04 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/62 , C12N15/66 , C12P21/02 , C12P21/08 , C12R1/19
CPC分类号： C07K16/32 , C07K16/22 , C07K16/30 , C07K16/3015 , C07K16/3069 , A61K2039/505 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C07K2319/55
摘要： Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

6. 发明授权

US4938948A Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies 失效
标题翻译：使用标记的单克隆抗 - 人乳腺癌抗体对乳腺肿瘤进行成像的方法
公开(公告)号：US4938948A
公开(公告)日：1990-07-03
申请号：US786948
申请日：1985-10-11
申请人： David B. Ring , Arthur E. Frankel
发明人： David B. Ring , Arthur E. Frankel
IPC分类号： C12N15/02 , A61K39/395 , A61K49/00 , A61K51/00 , A61K51/10 , A61P31/12 , C07K16/30 , C12N5/00 , C12N5/10 , C12N15/00 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/574 , G01N33/577
CPC分类号： A61K49/0058 , A61K51/10 , A61K51/1093 , C07K16/3015 , Y10S424/804 , Y10S424/807 , Y10S435/948 , Y10S530/808 , Y10S530/861
摘要： Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivity.Immunoimaging agents comprising the monoclonal antibody and a detectable label, either directly or indirectly conjugated to the antibody are claimed. Methods for imaging breast tumors using the immunoimaging agents are described and claimed.
摘要翻译：要求生产适用于人乳腺肿瘤和这种单克隆抗体成像和诊断的单克隆抗体的杂交瘤。单克隆抗体的特征在于乳腺肿瘤结合范围，乳腺癌细胞系范围和选择性。要求包含与抗体直接或间接缀合的单克隆抗体和可检测标记的免疫成像剂。描述和要求保护使用免疫成像剂对乳腺肿瘤成像的方法。

7. 发明授权

US4753894A Monoclonal anti-human breast cancer antibodies 失效
标题翻译：单克隆抗人乳腺癌抗体
公开(公告)号：US4753894A
公开(公告)日：1988-06-28
申请号：US690750
申请日：1985-01-11
申请人： Arthur E. Frankel , David B. Ring , Michael J. Bjorn
发明人： Arthur E. Frankel , David B. Ring , Michael J. Bjorn
IPC分类号： G01N33/574 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/005 , C07K14/195 , C07K16/00 , C07K16/30 , C07K19/00 , C12N5/00 , C12N5/10 , C12N5/18 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , C12Q1/02 , C12R1/19 , C12R1/91 , G01N33/53 , G01N33/577 , G01N33/54
CPC分类号： C07K16/3015 , A61K38/00 , C07K2317/24 , C07K2317/622 , Y10S424/804 , Y10S435/948 , Y10S530/808 , Y10S530/861 , Y10S530/864
摘要： Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
摘要翻译：制备和表征鼠单克隆抗体，其选择性结合人乳腺癌细胞，IgG或IgM，当与蓖麻毒蛋白A链缀合时，对MCF-7，CAMA-1，SKBR-3中的至少一种显示TCID为50％，或小于约10nM的BT-20细胞。描述了用由其制备的抗体或免疫毒素来诊断，监测和治疗人乳腺癌的方法。

8. 发明授权

US4569915A P. obtusus strain 失效
标题翻译：鹿角us属
公开(公告)号：US4569915A
公开(公告)日：1986-02-11
申请号：US583166
申请日：1984-02-24
申请人： David B. Ring
发明人： David B. Ring
IPC分类号： C12N9/04 , C12N1/14 , C12P19/22 , C12R1/645
CPC分类号： C12N9/0006 , C12R1/645 , Y10S435/911
摘要： A P. obtusus strain AU124 having the identifying characteristics of NRRL No. 15595, the strain produces high levels of pyranose-2-oxidase.
摘要翻译：具有NRRL No.15595的鉴定特征的P. obtusus菌株AU124，该菌株产生高水平的吡喃糖-2-氧化酶。

9. 发明授权

US6153618A Inhibitors of glycogen synthase 3 kinase 失效
标题翻译：糖原合成酶3激酶抑制剂
公开(公告)号：US6153618A
公开(公告)日：2000-11-28
申请号：US948887
申请日：1997-10-10
申请人： Peter Schultz , David B. Ring , Stephen D. Harrison , Andrew M. Bray
发明人： Peter Schultz , David B. Ring , Stephen D. Harrison , Andrew M. Bray
IPC分类号： C07D473/16 , A61K31/52
CPC分类号： C07D473/16
摘要： Compounds of formula 1: ##STR1## wherein R.sub.1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;R.sub.2 is hydroxy, amino, or lower alkoxy;R.sub.3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amnino-acyl;R.sub.4 is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.
摘要翻译：式1化合物：其中R 1是被0-3个选自低级烷基，卤素，羟基，低级烷氧基，氨基，低级烷基 - 氨基和硝基的取代基取代的烷基，环烷基，芳基，芳烷基，杂芳基或杂芳烷基。 R2是羟基，氨基或低级烷氧基; R3是H，低级烷基，低级酰基，低级烷氧基 - 酰基或氨基 - 酰基; R4是H或低级烷基; 及其药学上可接受的盐和酯; 是GSK3的有效抑制剂。

10. 发明授权

US6054561A Antigen-binding sites of antibody molecules specific for cancer antigens 失效
标题翻译：针对癌症抗原的抗体分子的抗原结合位点
公开(公告)号：US6054561A
公开(公告)日：2000-04-25
申请号：US483749
申请日：1995-06-07
申请人： David B. Ring
发明人： David B. Ring
IPC分类号： C07K16/32 , C07K16/18 , C07K16/28 , C07K16/30
CPC分类号： C07K16/32 , C07K2317/24 , C07K2317/622
摘要： Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell expressing an antigen selected from the group consisting of high molecular weight mucins bound by 2G3 and 369F10, c-erbB-2 tumor antigen, an approximately 42 kD glycoprotein, an approximately 55 kD glycoprotein, and the approximately 40, 60, 100 and 200 kD antigens bound by 113F1. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
摘要翻译：提供衍生自对癌抗原具有亲和力的免疫球蛋白的抗原结合位点的新型组合物。该组合物表现出能够特异性结合表达选自由2G3和369F10，c-erbB-2肿瘤抗原，约42kD糖蛋白结合的高分子量粘蛋白的抗原的抗原分子的免疫学结合特性约55kD的糖蛋白，以及由113F1结合的约40,60,100和200kD的抗原。提供了许多合成分子，其包括衍生自相同或不同免疫球蛋白部分的CDR和FR区。还提供了单链多肽，其中VH和VL结构域通过单个多肽接头连接。 sFv分子可以包括可以是生物活性的辅助多肽部分，或提供其它有用部分的连接位点。组合物可用于特异性结合测定，亲和纯化方案，靶向药物或毒素，成像以及各种癌症的遗传或免疫治疗。因此，本发明提供了新的多肽，编码那些多肽的DNA，包含那些DNA的表达盒，以及诱导多肽的产生的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式